181 related articles for article (PubMed ID: 9860377)
1. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
2. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
3. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Lim PO; Yee KM
Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
[No Abstract] [Full Text] [Related]
4. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
5. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
[TBL] [Abstract][Full Text] [Related]
7. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
8. Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Elam MB; Cushman W; Applegate WB; Heimberg M
Tenn Med; 1997 May; 90(5):189-92. PubMed ID: 9130876
[No Abstract] [Full Text] [Related]
9. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol-lowering drugs for primary prevention? The WOSCOP Study.
Muntoni S
Pharmacol Res; 1997 Mar; 35(3):169-70. PubMed ID: 9229402
[No Abstract] [Full Text] [Related]
11. Are we aggressive enough in lowering cholesterol?
Waters DD
Am J Cardiol; 2001 Aug; 88(4A):10F-5F. PubMed ID: 11520481
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of coronary artery disease.
Domanski MJ
N Engl J Med; 2007 Oct; 357(15):1543-5. PubMed ID: 17928603
[No Abstract] [Full Text] [Related]
13. Extending the benefit of lipid-regulating therapy to primary prevention.
Jones PH; Gotto AM
Am J Cardiol; 1995 Sep; 76(9):118C-121C. PubMed ID: 7572680
[TBL] [Abstract][Full Text] [Related]
14. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group.
J Clin Epidemiol; 1992 Aug; 45(8):849-60. PubMed ID: 1624967
[TBL] [Abstract][Full Text] [Related]
15. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
16. [LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]].
Homma Y
Nihon Rinsho; 2001 Mar; 59 Suppl 3():416-21. PubMed ID: 11347106
[No Abstract] [Full Text] [Related]
17. Cholesterol and coronary heart disease: new data from the WOSCOP Study.
Poli A
Pharmacol Res; 1997 Mar; 35(3):171-2. PubMed ID: 9229403
[No Abstract] [Full Text] [Related]
18. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).
Basso F; Lowe GD; Rumley A; McMahon AD; Humphries SE
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):599-604. PubMed ID: 11950697
[TBL] [Abstract][Full Text] [Related]
20. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
